SG10201604304RA - Radiolabelled glutaminyl cyclase inhibitors - Google Patents

Radiolabelled glutaminyl cyclase inhibitors

Info

Publication number
SG10201604304RA
SG10201604304RA SG10201604304RA SG10201604304RA SG10201604304RA SG 10201604304R A SG10201604304R A SG 10201604304RA SG 10201604304R A SG10201604304R A SG 10201604304RA SG 10201604304R A SG10201604304R A SG 10201604304RA SG 10201604304R A SG10201604304R A SG 10201604304RA
Authority
SG
Singapore
Prior art keywords
glutaminyl cyclase
cyclase inhibitors
radiolabelled
radiolabelled glutaminyl
inhibitors
Prior art date
Application number
SG10201604304RA
Other languages
English (en)
Inventor
Ulrich Heiser
Daniel Ramsbeck
Hans-Ulrich Demuth
Original Assignee
Probiodrug Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probiodrug Ag filed Critical Probiodrug Ag
Publication of SG10201604304RA publication Critical patent/SG10201604304RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/04X-ray contrast preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SG10201604304RA 2011-05-27 2012-05-24 Radiolabelled glutaminyl cyclase inhibitors SG10201604304RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161490654P 2011-05-27 2011-05-27

Publications (1)

Publication Number Publication Date
SG10201604304RA true SG10201604304RA (en) 2016-07-28

Family

ID=46149465

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201604304RA SG10201604304RA (en) 2011-05-27 2012-05-24 Radiolabelled glutaminyl cyclase inhibitors
SG2013081567A SG194770A1 (en) 2011-05-27 2012-05-24 Radiolabelled glutaminyl cyclase inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2013081567A SG194770A1 (en) 2011-05-27 2012-05-24 Radiolabelled glutaminyl cyclase inhibitors

Country Status (14)

Country Link
US (2) US8945510B2 (enExample)
EP (1) EP2714098A1 (enExample)
JP (1) JP2014515364A (enExample)
KR (1) KR20140028076A (enExample)
CN (1) CN103561776B (enExample)
AU (1) AU2012264951A1 (enExample)
BR (1) BR112013030341A2 (enExample)
CA (1) CA2835014A1 (enExample)
EA (1) EA028533B1 (enExample)
IL (1) IL229187A (enExample)
MX (1) MX2013013946A (enExample)
SG (2) SG10201604304RA (enExample)
WO (1) WO2012163773A1 (enExample)
ZA (1) ZA201308329B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2904465C (en) 2013-03-15 2021-07-13 Probiodrug Ag Inhibitors of glutaminyl cyclase
CN104230778B (zh) * 2014-07-14 2017-01-04 大连大学 β-烃氧酰基-γ-烃基-N-烃基-γ-丁内酰胺的合成方法
MY195016A (en) 2014-08-04 2023-01-03 Nuevolution As Optionally Fused Heterocyclyl-Substituted Derivatives of Pyrimidine Useful for The Treatment of Inflammatory, Metabolic, Oncologic and Autoimmune Diseases
US10513515B2 (en) 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
US11236103B2 (en) 2018-07-27 2022-02-01 Biotheryx, Inc. Bifunctional compounds
KR102230832B1 (ko) * 2019-06-17 2021-03-24 (주) 메디프론디비티 N-치환된 티오우레아 또는 우레아 유도체 및 이를 유효성분으로 함유하는 글루타미닐 사이클레이즈 활성 관련 질환의 예방 또는 치료용 약학적 조성물
US11447479B2 (en) 2019-12-20 2022-09-20 Nuevolution A/S Compounds active towards nuclear receptors
TWI872177B (zh) 2019-12-20 2025-02-11 丹麥商紐韋盧森公司 對核受體具有活性之化合物
MX2022012260A (es) 2020-03-31 2022-11-30 Nuevolution As Compuestos activos frente a receptores nucleares.
US11613532B2 (en) 2020-03-31 2023-03-28 Nuevolution A/S Compounds active towards nuclear receptors
US11897930B2 (en) 2020-04-28 2024-02-13 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT712759A (enExample) 1963-01-09
US5304367A (en) * 1990-11-16 1994-04-19 New York University In vivo brain imaging agent and method for diagnosis of psychiatric disorders
US7732162B2 (en) * 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
AU2005210004B2 (en) * 2004-02-05 2010-10-28 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
EP2808020A1 (en) 2006-04-21 2014-12-03 The Government Of The United States, As Represented by The Secretary Of Health And Human Services Beta-Amyloid Pet Imaging Agents
US8278345B2 (en) * 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
EA025107B1 (ru) * 2008-07-31 2016-11-30 Пробиодруг Аг Способ диагностирования болезни альцгеймера, нейродегенерации при синдроме дауна или легкого когнитивного нарушения у субъекта (варианты) и набор для осуществления способа
CN102186475B (zh) * 2008-09-04 2016-08-03 前体生物药物股份公司 新抑制剂
ES2797523T3 (es) 2009-03-23 2020-12-02 Lilly Co Eli Agentes de obtención de imagen para detectar trastornos neurológicos
US8486940B2 (en) * 2009-09-11 2013-07-16 Probiodrug Ag Inhibitors
EP2545047B9 (en) 2010-03-10 2015-06-10 Probiodrug AG Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)

Also Published As

Publication number Publication date
EA201301334A1 (ru) 2014-05-30
MX2013013946A (es) 2014-01-31
US9610368B2 (en) 2017-04-04
CN103561776A (zh) 2014-02-05
US8945510B2 (en) 2015-02-03
IL229187A (en) 2017-04-30
CA2835014A1 (en) 2012-12-06
EA028533B1 (ru) 2017-11-30
CN103561776B (zh) 2016-08-31
US20120301398A1 (en) 2012-11-29
SG194770A1 (en) 2013-12-30
KR20140028076A (ko) 2014-03-07
JP2014515364A (ja) 2014-06-30
ZA201308329B (en) 2015-02-25
NZ617581A (en) 2016-03-31
EP2714098A1 (en) 2014-04-09
WO2012163773A1 (en) 2012-12-06
US20150104389A1 (en) 2015-04-16
BR112013030341A2 (pt) 2016-11-29
AU2012264951A1 (en) 2013-12-12
IL229187A0 (en) 2013-12-31

Similar Documents

Publication Publication Date Title
IL273079B (en) Heterocycloamines as pi3k inhibitors
ZA201308329B (en) Radiolabelled glutaminyl cyclase inhibitors
ZA201307016B (en) Glucosylceramide synthase inhibitors
PL2710007T3 (pl) Inhibitory kinazy
ZA201404156B (en) Kinase inhibitors
EP2782580A4 (en) SELECTIVE INHIBITORS OF KINASES
IL229028A0 (en) Kinase inhibitors
GB201009731D0 (en) Kinase inhibitors
ZA201404157B (en) Kinase inhibitors
GB201112157D0 (en) New use of glutaminyl cyclase inhibitors
GB201018597D0 (en) Inhibitors
GB201120474D0 (en) Inhibitors
SG10201602021WA (en) Glucosylceramide synthase inhibitors